 The multiple-dose escalation Phase I clinical trial is expected to enroll 72 healthy subjects, and the enrollment is expected to be completed in the first quarter of 2023 Ascletis has filed global patent applications for ASC11 and related compounds and their use in viral disease HANGZHOU and SHAOXING, China, Jan. 15, 2023 PRNewswire Ascletis ...... 